Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.
He has an MA from University of Sioux Falls. You can connect with Jared on LinkedIn.
Male, White, Older Patients With Leukemia at Heightened Risk of Suicide, Study Finds
November 11th 2020In what is believed to be the first study of its kind, investigators found patients with leukemia face a higher risk of suicide than the general public, especially if they had acute myeloid leukemia.
Read More
Patients With ALL Have High Readmission Risk Post Chemotherapy, but Hospitals Can Change That
November 5th 2020Many patients with acute lymphoblastic leukemia (ALL) who undergo chemotherapy end up back in the hospital within 30 days. A new study points out the reasons and opportunities for prevention.
Read More
Use of Triplet Therapy Rose in R/R MM as Deaths Declined, Study Finds
October 29th 2020Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.
Read More
Prior Malignancy Linked to Risk of Secondary Malignancy in Follicular Lymphoma
October 29th 2020Previous research has found a link between a prior malignancy and secondary primary malignancy risk in patients with multiple myeloma. A new study suggests a similar association in follicular lymphoma.
Read More
Dual US, China Approval Process for Zanubrutinib Shows Regulatory Differences
October 7th 2020The process of approving a new therapy for relapsing and/or remitting mantle cell lymphoma therapy got off to a faster start in China, but United States regulators caught up and approved the drug first.
Read More
Case Report: Ibrutinib Might Protect Against Acute Lung Injury in Patients With CLL, COVID-19
October 2nd 2020A patient with chronic lymphocytic leukemia (CLL) was continued on ibrutinib even after developing severe coronavirus disease 2019 (COVID-19). He successfully overcame the infection.
Read More
HSCT Viable for Children With Nonremission Acute Lymphoblastic Leukemia
September 30th 2020Research into children and adolescents with nonremission acute lymphoblastic leukemia (ALL) has been sparse, but a new analysis suggests that allogeneic hematopoietic stem cell transplantation is a good fit for some patients.
Read More
TKI Leads to Superior Outcomes in ALL With an ABL-Class Fusion, Study Says
September 23rd 2020Patients with acute lymphoblastic leukemia (ALL) who have an ABL-class fusion had better outcomes than a control group when treated with tyrosine kinase inhibitors at their first relapse, according to a new study.
Read More